GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enorama Pharma AB (OSTO:ERMA) » Definitions » EV-to-Revenue

Enorama Pharma AB (OSTO:ERMA) EV-to-Revenue : 101.86 (As of May. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Enorama Pharma AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Enorama Pharma AB's enterprise value is kr138.33 Mil. Enorama Pharma AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was kr1.36 Mil. Therefore, Enorama Pharma AB's EV-to-Revenue for today is 101.86.

The historical rank and industry rank for Enorama Pharma AB's EV-to-Revenue or its related term are showing as below:

OSTO:ERMA' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.32   Med: 39.47   Max: 509.64
Current: 101.86

During the past 10 years, the highest EV-to-Revenue of Enorama Pharma AB was 509.64. The lowest was 2.32. And the median was 39.47.

OSTO:ERMA's EV-to-Revenue is ranked worse than
96.58% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs OSTO:ERMA: 101.86

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-27), Enorama Pharma AB's stock price is kr2.35. Enorama Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.04. Therefore, Enorama Pharma AB's PS Ratio for today is 60.26.


Enorama Pharma AB EV-to-Revenue Historical Data

The historical data trend for Enorama Pharma AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enorama Pharma AB EV-to-Revenue Chart

Enorama Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.52 91.54 14.73 4.66 89.21

Enorama Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.66 18.15 19.67 114.90 89.21

Competitive Comparison of Enorama Pharma AB's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enorama Pharma AB's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Enorama Pharma AB's EV-to-Revenue falls into.



Enorama Pharma AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Enorama Pharma AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=138.326/1.358
=101.86

Enorama Pharma AB's current Enterprise Value is kr138.33 Mil.
Enorama Pharma AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enorama Pharma AB  (OSTO:ERMA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Enorama Pharma AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.35/0.039
=60.26

Enorama Pharma AB's share price for today is kr2.35.
Enorama Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enorama Pharma AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Enorama Pharma AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Enorama Pharma AB (OSTO:ERMA) Business Description

Traded in Other Exchanges
N/A
Address
Sodergatan 3, Malmo, SWE, SE-211 34
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.

Enorama Pharma AB (OSTO:ERMA) Headlines

No Headlines